



Trajenta

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IAIN/0047/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.5.a - Administrative change - Change in the name	13/12/2021		Annex II and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	and/or address of a manufacturer/importer responsible for batch release				
N/0045	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/04/2021	27/05/2021	PL	
IB/0044	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	21/12/2020	n/a		
WS/1835	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	02/07/2020	n/a		
IB/0043/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-	08/06/2020	27/05/2021	Annex II and PL	

	<p>release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.c.z - Change in control of excipients in the Finished Product - Other variation</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>				
WS/1696/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a</p>	16/01/2020	n/a		

<p>starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size</p> <p>B.I.b.z - Change in control of the AS - Other variation</p> <p>B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
--	--	--	--	--

	<p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>				
N/0041	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/01/2020	09/03/2020	PL	
WS/1601	This was an application for a variation following a	31/10/2019	09/03/2020	SmPC and PL	The MAH updated sections 4.2 and 5.1 of the Trajenta

	<p>worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.2 and 5.1 of the Trajenta SmPC, update of sections 4.2, 4.4 and 5.1 of the Jentaduetto SmPC and section 5.1 of the Glyxambi SmPC, based on the final results from study 1218.74 (CAROLINA study) listed as a category 3 study in the RMP of Jentaduetto and Trajenta, in order to fulfil Trajenta MEA 008.1 and Jentaduetto MEA 001.1; this is a phase III randomized, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The Package Leaflet for Trajenta is updated accordingly. The RMP version 13.1 for Jentaduetto and Trajenta and version 5.1 for Glyxambi have also been submitted. In addition, the Worksharing applicant (WSA) took the opportunity to make corrections throughout the product information for Glyxambi and Jentaduetto and to make corrections to the Bulgarian, French, Swedish translations for Glyxambi.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>				<p>SmPC, sections 4.2, 4.4 and 5.1 of the Jentaduetto SmPC and section 5.1 of the Glyxambi SmPC, based on the final results from study 1218.74 (CAROLINA study). The double-blind parallel group CAROLINA study evaluated the cardiovascular safety of linagliptin versus glimepiride as adjunct to standard care therapy in patients with type 2 diabetes and with increased CV risk. A total of 6033 patients were treated (linagliptin 5 mg: 3023, glimepiride 1 mg to 4 mg: 3010) and followed for a median of 6.25 years. The mean age was 64 years, the mean HbA1c was 7.15 %, and 60 % were male. Approximately 19 % of the population had an eGFR <60 mL/min/1.73 m². The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI) or a non-fatal stroke (3P-MACE). Linagliptin did not increase the risk of the combined endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke (MACE-3) [Hazard Ratio (HR)=0.98; (95 % CI 0.84, 1.14); p<0.0001 for non-inferiority], when added to standard of care in adult patients with type 2 diabetes with increased CV risk compared to glimepiride.</p>
IB/0039	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	23/07/2019	09/03/2020	SmPC and PL	
IB/0037/G	This was an application for a group of variations.	02/05/2019	09/03/2020	Annex II and	

	<p>B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p> <p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation</p> <p>B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation</p> <p>B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete</p>			PL	
--	--	--	--	----	--

	parameter)				
IG/1077	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	14/03/2019	n/a		
WS/1461	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.4 , 4.8 and 5.1 of the SmPC to update the warnings related to acute pancreatitis and bullous pemphigoid and the efficacy and safety information based on final results from study listed as a category 3 in the RMP "A multicenter, international, randomized, parallel group, double blind, placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk (CARMELINA)". The RMP have also been updated accordingly for all products (Trajenta and Jentaduetto version 12.1, Glyxambi version 4.1) and to be in accordance with the revision 2 of the RMP template.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	14/03/2019	09/03/2020	SmPC	The SmPC sections 4.4, 4.8 and 5.1 have been updated to reflect the results of CARMELINA study on acute pancreatitis and bullous pemphigoid and on the efficacy and safety information of linagliptin. CARMELINA study evaluated the cardiovascular and renal safety of linagliptin 5 mg once daily versus placebo as adjunct to standard care therapy in patients with type 2 diabetes and with increased cardiovascular risk evidenced by a history of established macrovascular or renal disease.

WS/1469	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation</p>	17/01/2019	n/a		
PSUSA/10427 /201805	Periodic Safety Update EU Single assessment - linagliptin, linagliptin / metformin	29/11/2018	n/a		PRAC Recommendation - maintenance
N/0032	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	26/06/2018	09/03/2020	PL	
WS/1201/G	<p>This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.e - Change in test procedure for AS or</p>	14/09/2017	n/a		

	starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
IB/0030	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	12/07/2017	n/a		
WS/1162	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	01/06/2017	12/03/2018	SmPC	
IG/0798/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name	05/05/2017	n/a		

	<p>and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>				
WS/1140	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation</p>	23/03/2017	12/03/2018	SmPC and PL	
WS/0915	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Extension of indication to include the use of Trajenta and Jentadueto in combination with other diabetes medicines; as a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated based on studies 1245.30, 1275.10 and 1275.1. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to make minor editorial changes in the PI. Moreover, the RMP version 10 (for Trajenta) and version 12 (for Jentadueto) have been updated. Furthermore, the PI is brought in line with the latest QRD template</p>	15/12/2016	27/01/2017	SmPC and PL	Please refer to the Scientific Discussion for Trajenta /Jentadueto H/C/WS0915.

	version 10.0. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
IA/0026	B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation	14/09/2016	n/a		
IB/0025	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	28/06/2016	n/a		
IA/0024	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	09/06/2016	n/a		
II/0023	Update of section 4.8 of the SmPC in order to update ADR frequency categories based on the pooled safety analysis of the placebo-controlled trials undertaken. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	28/04/2016	27/01/2017	SmPC and PL	Compared with the previous ADR frequency update, 'hypersensitivity' has changed frequency category from 'not known' to 'uncommon' for linagliptin monotherapy, linagliptin+metformin+sulphonylurea, and linagliptin+insulin combinations, and from 'rare' to 'uncommon' for the linagliptin+metformin combination. Compared with the previous ADR frequency update, 'amylase increased' has changed frequency category from 'uncommon' to 'rare' for linagliptin monotherapy, and from 'not known' to 'uncommon' for the linagliptin+metformin+sulphonylurea combination.

R/0021	Renewal of the marketing authorisation.	28/01/2016	22/03/2016	SmPC, Labelling and PL	
PSUSA/1886/ 201505	Periodic Safety Update EU Single assessment - linagliptin	17/12/2015	18/02/2016	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1886/201505.
N/0019	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/07/2015	23/09/2015	PL	
II/0018	Submission of a revised RMP in order to add cardiac failure as important potential risk. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	21/05/2015	n/a		
PSUV/0016	Periodic Safety Update	04/12/2014	n/a		PRAC Recommendation - maintenance
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	27/11/2014	23/09/2015	PL	
WS/0524	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure	25/09/2014	23/09/2015	SmPC and PL	

	concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH				
IG/0432	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	16/04/2014	n/a		
IB/0013	B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	20/12/2013	n/a		
IAIN/0012	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	22/11/2013	n/a		
IG/0350	C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring	30/08/2013	18/09/2014	SmPC and PL	
N/0010	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/08/2013	18/09/2014	PL	
WS/0356	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC in order to update the information with the current data from the	21/03/2013	22/04/2013	SmPC	In this variation the MAH has provided an update of the prospective CV meta-analysis. A first analysis of this study was submitted with the MAA. Additionally an updated summary was performed in 2011 to support the types II variation for the add-on to insulin indication (EMA/H/C/002110/II/0004/G).

	<p>cardiovascular risk meta-analysis.</p> <p>C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data</p>				<p>Compared to earlier analyses no significant changes have been observed.</p> <p>In total there were 60 primary events on linagliptin and 62 on comparators. The overall CV risk ratio was not significantly reduced for linagliptin versus combined comparators. No difference in CV risk for linagliptin was observed versus placebo in the placebo-controlled trials only. The secondary and tertiary composite CV endpoints also do not show an increased risk for linagliptin as compared with combined comparators.</p> <p>Section 5.1 of the SmPC has been updated to reflect this new data.</p>
WS/0351	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.8 of the SmPC in order to include the new adverse reaction "rash" following a CHMP request after the evaluation of the latest PSUR. The Package Leaflet was updated accordingly.</p> <p>In addition, the MAH took the opportunity to implement minor typographical corrections in the SmPC.</p> <p>Furthermore, Annex II was updated to reflect the latest version of the QRD template.</p> <p>C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the</p>	21/03/2013	22/04/2013	SmPC, Annex II and PL	<p>Following the assessment of the latest PSUR for linagliptin, the CHMP requested that, considering the reported de- and re-challenge cases, "rash" should be clearly included as a new adverse reaction in the product information.</p> <p>The MAH has complied with the mentioned CHMP request. Based on the incidence of "rash" in clinical trials (0.4%), frequency uncommon was proposed to be assigned, and the CHMP considered it to be acceptable.</p> <p>Furthermore, the MAH proposals to:</p> <ul style="list-style-type: none"> - change of the frequency of "hypersensitivity" from uncommon to rare and - addition of "urticaria" and "angioedema" to the SOC "Skin and subcutaneous tissue disorders" with the frequency rare. For these ADRs an asterix is used to indicate that these events were derived from post-marketing experience; <p>were in line with the conclusions of PSUR-2 and therefore were considered acceptable by the CHMP.</p> <p>The other proposed changes and corrections to the SmPC</p>

	MAH				and PL were accepted. Based on the information presented by the MAH to support this variation, there is no impact on the overall benefit/risk balance.
II/0004/G	<p>This was an application for a group of variations.</p> <p>This was an application for a group of variations. Update of sections 4.1, 4.2, 4.4, 4.7, 4.8 and 5.1 of the SmPC: extension of indication for the treatment of type 2 diabetes in combination with insulin (with or without metformin) when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. Sections 1, 2 and 4 of the Package Leaflet are updated accordingly.</p> <p>Update of sections 4.2, 4.8 and 5.1 of the SmPC to include the results of study 1218.63, a study conducted in elderly patients.</p> <p>In addition, the MAH took the opportunity to include the Marketing Authorisation numbers in the SmPC and Labelling and to make linguistic corrections in the Spanish Annexes.</p> <p>Furthermore, the PI is being brought in line with the latest QRD template version 8.</p> <p>The requested group of variations proposed amendments to the Update of Summary of Product Characteristics, Annex II, Labelling and Package Leaflet.</p> <p>C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one</p>	20/09/2012	24/10/2012	SmPC, Annex II, Labelling and PL	For further information please refer to the scientific conclusion: Trajenta H-2110-II-04-G-AR.

	C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data				
IB/0007/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	02/10/2012	n/a		
IG/0211	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	05/09/2012	n/a		
IA/0006	A.7 - Administrative change - Deletion of manufacturing sites	28/08/2012	n/a		
WS/0255/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the Description of Pharmacovigilance System (DDPS). C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS - Other variation C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS - Other variation	24/05/2012	24/05/2012		Changes to an existing pharmacovigilance system as described in the DDPS. The MAH update the Detailed Description of the Pharmacovigilance System (DDPS) for Aptivus, MicardisPlus, Mirapexin, Onduarp, Pradaxa, Sifrol, Trajenta, Twynsta and Viramune.

	<p>C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing pharmacovigilance activities</p> <p>C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database</p> <p>C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV</p> <p>C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system</p>				
IA/0002	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	15/03/2012	n/a		
N/0001	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/03/2012	24/10/2012	PL	